Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 4;18(8):1702.
doi: 10.3390/ijms18081702.

Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome

Jacek Rysz  1 , Anna Gluba-Brzózka  2 , Beata Franczyk  3 , Zbigniew Jabłonowski  4 , Aleksandra Ciałkowska-Rysz  5
Affiliations
Review

Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome

Jacek Rysz et al. Int J Mol Sci. .

Abstract

In its early stages, symptoms of chronic kidney disease (CKD) are usually not apparent. Significant reduction of the kidney function is the first obvious sign of disease. If diagnosed early (stages 1 to 3), the progression of CKD can be altered and complications reduced. In stages 4 and 5 extensive kidney damage is observed, which usually results in end-stage renal failure. Currently, the diagnosis of CKD is made usually on the levels of blood urea and serum creatinine (sCr), however, sCr has been shown to be lacking high predictive value. Due to the development of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, the introduction of novel techniques will allow for the identification of novel biomarkers in renal diseases. This review presents some new possible biomarkers in the diagnosis of CKD and in the prediction of outcome, including asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), uromodulin, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), miRNA, ncRNA, and lincRNA biomarkers and proteomic and metabolomic biomarkers. Complicated pathomechanisms of CKD development and progression require not a single marker but their combination in order to mirror all types of alterations occurring in the course of this disease. It seems that in the not so distant future, conventional markers may be exchanged for new ones, however, confirmation of their efficacy, sensitivity and specificity as well as the reduction of analysis costs are required.

Keywords: ADMA; KIM-1; NGAL; SDMA; biomarkers; chronic kidney disease; lincRNA and proteomic and metabolomic biomarkers; miRNA; ncRNA; uromodulin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of miRNA action (figure was prepared and modified on the basis of [92]).
Figure 2
Figure 2
Mechanisms of action of lncRNA (figure was prepared and modified on the basis of [93]).The actions of lncRNA involve the interfering with protein-DNA binding, the regulation of mRNA stability and translation, the alteration of protein function, the organization of nuclear architecture and the modulation of mRNA levels and finally they are associated with the above mechanisms.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Khan Z., Pandey M. Role of kidney biomarkers of chronic kidney disease: An update. Saudi J. Biol. Sci. 2014;21:294–299. doi: 10.1016/j.sjbs.2014.07.003. - DOI - PMC - PubMed
    1. Viau A., Karoui K.E., Laouari D., Burtin M., Nguyen C., Mori K., Pillebout E., Berger T., Mak T.W., Knebelmann B., et al. Lipocalin 2 is essential for chronic kidney disease in mice and human. J. Clin. Investig. 2010;120:4065–4076. doi: 10.1172/JCI42004. - DOI - PMC - PubMed
    1. Hostetter T.H. Progression of renal disease and renal hypertrophy. Annu. Rev. Physiol. 1995;57:263–278. doi: 10.1146/annurev.ph.57.030195.001403. - DOI - PubMed
    1. Kliem V., Johnson R.J., Alpers C.E., Yoshimura A., Couser W.J., Koch K.M., Floege J. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996;49:666–678. doi: 10.1038/ki.1996.95. - DOI - PubMed
    1. Pillebout E., Weitzman J.B., Burtin M., Martino C., Federici P., Yaniv M., Friedlander G., Terzi F. JunD protects against chronic kidney disease by regulating paracrine mitogens. J. Clin. Investig. 2003;112:843–852. doi: 10.1172/JCI200317647. - DOI - PMC - PubMed

LinkOut - more resources